Drug Profile
Research programme: inflammation therapeutics - Centocor/Shanghai Genomics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Centocor; Shanghai Genomics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in China
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in China
- 25 Jul 2006 Preclinical trials in Cancer in China (unspecified route)